Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 5, 2018Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their...
-
Jun 5, 2018RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
May 30, 2018- Designation underscores the need to expand potential treatment options to help certain young patients achieve goal of seizure freedom
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for its antiepileptic drug FYCOMPA®...
-
May 22, 2018
Companies will present data on: Postural stability after middle-of-the-night awakening and next-morning compared to zolpidem ER Auditory awakening threshold Return to sleep latency compared to...
-
Apr 19, 2018Abstracts presented add to growing body of FYCOMPA data supporting convulsive seizure freedom, and real-world, long-term safety & efficacy data
Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include...